Manulife Singapore has partnered with oncology treatment company Guardant to provide its customers access to the Guardant360 liquid biopsy test, according to a company release on Tuesday.
The company has also teamed up with AMILI which provides advanced gut microbiome screening.
The Guardant360 test carries out genomic profiling of advanced solid cancers and identifies biomarkers through blood samples.
Patients can see their results within seven days.
Through the partnership with AMILI, Manulife will be able provide its customers with personalized insights to improve their immunity, nutrition and brain health.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。